---
document_datetime: 2023-09-21 17:13:44
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vibativ-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: vibativ-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.849453
conversion_datetime: 2025-12-20 16:33:41.384122
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vibativ

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                      | Opinion/ Notification 1 issued on Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/2879/ 201703   | Periodic Safety Update EU Single assessment - telavancin                                   | 28/09/2017 n/a                                                                   |                                  | PRAC Recommendation - maintenance |
| IAIN/0031            | A.1 - Administrative change - Change in the name and/or address of the MAH product         | 08/09/2017                                                                       | SmPC, Labelling and PL           |                                   |
| IB/0029              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing | 21/04/2017                                                                       | Annex II                         |                                   |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                |            |               |                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2879/ 201609 | Periodic Safety Update EU Single assessment - telavancin                                                                                                                                                                                                                                                                                                                                                                                                                          | 06/04/2017 | n/a           |                                         | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| T/0027             | Application for Transfer of Marketing Authorisation from Clinigen Healthcare Ltd to Theravance Biopharma Ireland Ltd. Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                         | 06/10/2016 | 03/11/2016    | SmPC, Labelling and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/2879/ 201603 | Periodic Safety Update EU Single assessment - telavancin                                                                                                                                                                                                                                                                                                                                                                                                                          | 29/09/2016 | n/a           |                                         | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| R/0025             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                           | 01/04/2016 | 26/05/2016 no | SmPC, Annex II, Labelling and PL longer |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/2879/ 201509 | Periodic Safety Update EU Single assessment - telavancin                                                                                                                                                                                                                                                                                                                                                                                                                          | 14/04/2016 | n/a           |                                         | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0023            | Update of section 4.2 and 5.2 of the SmPC and Annex II of the Product Information in order to update the dose recommendation for obese patients and to remove the reference to PK obesity study following the assessment of ANX/001.1 post authorisation measure. The Package Leaflet is updated accordingly. Consequently an updated RMP ver.3 is provided. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance product | 28/01/2016 | 26/02/2016    | SmPC, Annex II and PL                   | Body mass index (BMI) at baseline was found to influence telavancin pharmacokinetics in the population pharmacokinetic analysis in healthy (without infection) adult subjects. Exposure to telavancin increases with increase in BMI; for each 10-unit increase in BMI, it is estimated that plasma exposure will increase by up to 25%. Obese patients (defined as those with BMI >30 kg/m2) should receive telavancin at the reduced dose of 7.5 mg/kg once every 24 hours. |

<div style=\"page-break-after: always\"></div>

|                    | data                                                                                                                                                                    |            |            |             |                                                                                                                                                             |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2879/ 201503 | Periodic Safety Update EU Single assessment - telavancin                                                                                                                | 08/10/2015 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                           |
| IAIN/0022          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location         | 01/07/2015 | n/a        |             |                                                                                                                                                             |
| IA/0020            | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                     | 08/05/2015 | n/a        | longer      |                                                                                                                                                             |
| PSUSA/2879/ 201409 | Periodic Safety Update EU Single assessment - telavancin                                                                                                                | 10/04/2015 | n/a no     |             | PRAC Recommendation - maintenance                                                                                                                           |
| IAIN/0018          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location         | 28/11/2014 | n/a        |             |                                                                                                                                                             |
| IAIN/0017          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location product | 10/10/2014 | n/a        |             |                                                                                                                                                             |
| PSUV/0014          | Periodic Safety Update                                                                                                                                                  | 09/10/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                           |
| II/0015            | Update of section 5.1 of the SmPC in order to implement the EUCAST approved breakpoint for Staphylococcus aureus (including methicillin resistant                       | 25/09/2014 | 30/09/2015 | SmPC and PL | In accordance with the EUCAST revised breakpoint and accepted abbreviation, the minimum inhibitory concentration (MIC) breakpoints for S. aureus (including |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

|           | strains). The MAH implemented some minor corrections in the Package Leaflet. In addition, the MAH took the opportunity to correct some typographical errors in the DE, ES, FR, IT, NL and PT translations of the Package Leaflet. The Annex A was corrected to include the correct pharmaceutical form 'powder for concentrate for solution for infusion'. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                   | methicillin resistant strains) has been changed to 0.12 Î¼g/ml. longer authorised   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| IAIN/0016 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the 12/08/2014 n/a no                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                    |
| PSUV/0013 | Periodic Safety Update 10/04/2014 n/a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | PRAC Recommendation - maintenance                                                  |
| II/0006/G | This was an application for a group of variations. - To replace Ben Venue Laboratories, Inc.as a site responsible for manufacture, primary packaging and stability of the finished product with a new site. - to replace a currently registered test method with a different Ph.Eur. test method for the finished product - to delete two manufacturing and batch release sites for the finished product - to delete two testing sites for the finished product - to add a packaging site for the finished product - to add a site responsible for batch release of the 23/01/2014 12/03/2014 Annex PL product |                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | finished product and - to add a testing site for the finished product vials. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   | product    | no longer   | authorised                        |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-----------------------------------|
| PSUV/0012 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 06/03/2014 | n/a         | PRAC Recommendation - maintenance |
| II/0009   | to change the batch size of the finished product for the 750 mg vials.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 23/01/2014 | n/a         |                                   |

<div style=\"page-break-after: always\"></div>

|         | B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                          |            |            |                        |                                                                                                                            |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------|
| II/0008 | to change the specification of the finished product. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                    | 23/01/2014 | n/a        | longer                 |                                                                                                                            |
| II/0007 | to introduce changes to the manufacturing process of the finished product B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product product | 23/01/2014 | n/a no     |                        |                                                                                                                            |
| T/0005  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                         | 24/07/2013 | 03/09/2013 | SmPC and PL            | New Marketing Authorisation Holder: Clinigen Healthcare Ltd Previous Marketing Authorisation Holder: Theravance UK Limited |
| T/0004  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                         | 21/12/2012 | 08/02/2013 | SmPC, Labelling and PL | New Marketing Authorisation Holder: Theravance UK Limited                                                                  |

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             | Pharma Europe B.V.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002     | To update the SmPC section 4.4 (Special warnings and precautions for use) and 4.8 ( Undesirable effects) with hypersensitivity reactions, including anaphylaxis. The Package Leaflet (PL) was proposed to be updated in accordance. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                       | 19/04/2012 | 08/02/2013 | SmPC and PL | Astellas The current approved SmPC of Vibativ already lists a number of manifestations of allergic type and infusion reactions that are highly likely to represent drug related reactions, including red man syndrome like reactions, including flushing of the upper body, urticaria, pruritus or rash. However, there is biologic plausibility for anaphylaxis and cross reactivity to vancomycin to occur after exposure to telavancin. Based on the cumulative review of the cases related to hypersensitivity reaction (inclusive anaphylaxis) and the literature review on anaphylaxis with other antibacterial agents, including glycopeptides, it is agreed to add 'hypersensitivity reactions, including anaphylaxis' to the SmPC. The PL is updated accordingly. The benefit-risk balance of Vibativ mg powder for concentrate for solution for infusion remains unchanged. longer authorised |
| IAIN/0003/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD product | 30/01/2012 | n/a no     |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system Medicinal product no longer authorised